We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ObsEva Ends Recruitment in Second Uterine Fibroids Study
Read MoreHide Full Article
ObsEva SA announced the completion of patient recruitment in its second pivotal phase III study, PRIMROSE 1, evaluating oral gonadotropin releasing hormone (GnRH) receptor antagonist, linzagolix, for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids (UF). Uterine fibroids are common non-cancerous tumors that grow within the muscular wall of the uterus.
PRIMROSE 1 will randomize about 500 patients who are diagnosed with HMB associated with UF. The patients will receive either a once daily dose of 100 mg or 200 mg of linzagolix, or placebo. Primary endpoint of PRIMROSE 1 is a clinically meaningful and statistically significant reduction in menstrual bleeding, as assessed by the alkaline hematin method, which is a validated, quantitative measurement of menstrual blood loss. Six-month primary endpoint data from the study are anticipated in the first half of 2020.
The company is also conducting another phase III study, PRIMROSE 2, simultaneously in the United States and Europe. The study is testing the same treatment arms at 102 sites, where about 500 patients have also been randomized. The company expects to report six-month primary endpoint data from the study in the fourth quarter of 2019.
The company’s shares have declined 11.5% year to date against the industry’s growth of 4.3%.
We remind investors that another pharma company, AbbVie Inc. (ABBV - Free Report) , is also evaluating elagolix for uterine fibroids. The candidate is in phase III studies and the company expects to file a new drug application this year.
Zacks Ranks and Stocks to Consider
ObsEvacurrently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Applied Genetics Technologies Corp. and Acorda Therapeutics Inc. . While Applied Genetics sports a Zacks Rank #1 (Strong Buy), Acorda carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Applied Genetics’ loss per share estimates have narrowed from $2.39 to $2.15 for 2020 in the past 90 days. The company surpassed estimates in three of the trailing four quarters, with average positive surprise of 83.47%.
Acorda’s loss per share estimates have narrowed from $3.16 to $3.09 for 2020 in the past 60 days. The company outpaced estimates in the trailing four quarters, the average being 79.32%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
ObsEva Ends Recruitment in Second Uterine Fibroids Study
ObsEva SA announced the completion of patient recruitment in its second pivotal phase III study, PRIMROSE 1, evaluating oral gonadotropin releasing hormone (GnRH) receptor antagonist, linzagolix, for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids (UF). Uterine fibroids are common non-cancerous tumors that grow within the muscular wall of the uterus.
PRIMROSE 1 will randomize about 500 patients who are diagnosed with HMB associated with UF. The patients will receive either a once daily dose of 100 mg or 200 mg of linzagolix, or placebo. Primary endpoint of PRIMROSE 1 is a clinically meaningful and statistically significant reduction in menstrual bleeding, as assessed by the alkaline hematin method, which is a validated, quantitative measurement of menstrual blood loss. Six-month primary endpoint data from the study are anticipated in the first half of 2020.
The company is also conducting another phase III study, PRIMROSE 2, simultaneously in the United States and Europe. The study is testing the same treatment arms at 102 sites, where about 500 patients have also been randomized. The company expects to report six-month primary endpoint data from the study in the fourth quarter of 2019.
The company’s shares have declined 11.5% year to date against the industry’s growth of 4.3%.
We remind investors that another pharma company, AbbVie Inc. (ABBV - Free Report) , is also evaluating elagolix for uterine fibroids. The candidate is in phase III studies and the company expects to file a new drug application this year.
Zacks Ranks and Stocks to Consider
ObsEvacurrently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Applied Genetics Technologies Corp. and Acorda Therapeutics Inc. . While Applied Genetics sports a Zacks Rank #1 (Strong Buy), Acorda carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Applied Genetics’ loss per share estimates have narrowed from $2.39 to $2.15 for 2020 in the past 90 days. The company surpassed estimates in three of the trailing four quarters, with average positive surprise of 83.47%.
Acorda’s loss per share estimates have narrowed from $3.16 to $3.09 for 2020 in the past 60 days. The company outpaced estimates in the trailing four quarters, the average being 79.32%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>